Leveraging Signaling Pathways to Treat Heart Failure with Reduced Ejection Fraction: Past, Present, and Future

Miguel Pinilla-Vera, Virginia S. Hahn, David A. Kass

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Advances in the treatment of heart failure with reduced ejection fraction due to systolic dysfunction are engaging an ever-expanding compendium of molecular signaling targets. Well established approaches modifying hemodynamics and cell biology by neurohumoral receptor blockade are evolving, exploring the role and impact of modulating intracellular signaling pathways with more direct myocardial effects. Even well-tread avenues are being reconsidered with new insights into the signaling engaged and thus opportunity to treat underlying myocardial disease. This review explores therapies that have proven successful, those that have not, those that are moving into the clinic but whose utility remains to be confirmed, and those that remain in the experimental realm. The emphasis is on signaling pathways that are tractable for therapeutic manipulation. Of the approaches yet to be tested in humans, we chose those with a well-established experimental history, where clinical translation may be around the corner. The breadth of opportunities bodes well for the next generation of heart failure therapeutics.

Original languageEnglish (US)
Pages (from-to)1618-1632
Number of pages15
JournalCirculation research
Issue number11
StatePublished - May 24 2019


  • G-coupled protein receptor
  • cardiomyopathy
  • inotrope
  • kinase
  • metabolism
  • phosphodiesterase
  • therapy

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Leveraging Signaling Pathways to Treat Heart Failure with Reduced Ejection Fraction: Past, Present, and Future'. Together they form a unique fingerprint.

Cite this